 |
|
|
Sandra Horning
Profile: http://med.stanford.edu/profiles/Sandra_Horning/
Contact: Academic Appointments
Appointment
Organization
Professor
Member
View Clinical Profile |
Honors & Awards
Title
Organization
Date(s)
Alwin C. Rambar-James B. D. Mark Award for Excellence in Patient Care
Stanford University School of Medicine
2000
Administrative Appointments
Title
Organization
Start Year
End Year
President
ASCO
2005
2006
President-Elect
ASCO
2004
2005
Postdoctoral Advisees
ChunFang Zhu
Research Interests
The objectives of the clinical research program are:
1. to improve therapeutic outcomes and/or reduce complications of treatment, and
2. to further elucidate the underlying biology of Hodgkin’s disease (HD) and the non-Hodgkin’s lymphomas (NHL).
The research program is highly collaborative and includes ongoing clinical trials with myeloablative therapy in HD and NHL with the Bone Marrow Transplant team, combined modality trials in HD with Radiation Oncology, clinical-pathologic correlative studies with Pathology, and drug development with an emphasis on targeted therapy for B-cell lymphoma (anti-CD20) with industrial collaborators.
Dr. Horning is chairman of the Lymphoma Committee for the Eastern Cooperative Oncology Group, a forum for extending pilot studies to multi-institutional trials. Dr. Horning supervises a sophisticated multi-relational Lymphoma Database which has information on over 15,000 patients, an excellent resource for prospective and retrospective clinical investigations
1. to improve therapeutic outcomes and/or reduce complications of treatment, and
2. to further elucidate the underlying biology of Hodgkin’s disease (HD) and the non-Hodgkin’s lymphomas (NHL).
The research program is highly collaborative and includes ongoing clinical trials with myeloablative therapy in HD and NHL with the Bone Marrow Transplant team, combined modality trials in HD with Radiation Oncology, clinical-pathologic correlative studies with Pathology, and drug development with an emphasis on targeted therapy for B-cell lymphoma (anti-CD20) with industrial collaborators.
Dr. Horning is chairman of the Lymphoma Committee for the Eastern Cooperative Oncology Group, a forum for extending pilot studies to multi-institutional trials. Dr. Horning supervises a sophisticated multi-relational Lymphoma Database which has information on over 15,000 patients, an excellent resource for prospective and retrospective clinical investigations
Publications
- Heidenreich PA, Schnittger I, Strauss HW, Vagelos RH, Lee BK, Mariscal CS, Tate DJ, Horning SJ, Hoppe RT, Hancock SL "Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease." J Clin Oncol 2007; 25: 1: 43-9 More »
- Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V "Revised Response Criteria for Malignant Lymphoma." J Clin Oncol 2007; More »
- Ganjoo K, Advani R, Mariappan MR, McMillan A, Horning S "Non-Hodgkin lymphoma of the breast." Cancer 2007; More »
- Advani R, Maeda L, Lavori P, Quon A, Hoppe R, Breslin S, Rosenberg SA, Horning SJ "Impact of Positive Positron Emission Tomography on Prediction of Freedom From Progression After Stanford V Chemotherapy in Hodgkin's Disease." J Clin Oncol 2007; More »
- Advani R, Horwitz S, Zelenetz A, Horning SJ "Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine." Leuk Lymphoma 2007; 48: 3: 521-5 More »
89 publications: view full list
